Epidemiologic evidence overwhelmingly supports the notion that estrogen-replacement therapy protects postmenopausal women from coronary artery disease. Still the appropriate treatment of these women with gonadal steroids remains controversial, since the benefits have been inferred from observation studies rather than demonstrated in prospective clinical trials. Preventive hormonal replacement therapy for postmenopausal women in general is unwarranted at present. The need for large-scale randomized trials of long term preventive hormone treatment is compelling. Almost all physicians believe that estrogen treatment can prevent osteoporosis, but on the basis of recent studies it can be concluded that estrogen therapy in the first decade after menopause cannot be expected to give enough protection against osteoporotic fractures decades later.
|Translated title of the contribution||Can the postmenopausal hormone replacement therapy be considered as a prevention of cardiovascular diseases and osteoporosis?|
|Number of pages||7|
|Publication status||Published - Jan 1 1995|
ASJC Scopus subject areas